J&J ends R&D at Janssen's infectious disease and vaccine unit

Biogen CEO’s tight-lipped zuranolone commentary not enough for Sage investors aarmstrong Wed, 07/26/2023 - 10:08Analysts and investors wanted the tea on the FDA review of Sage Therapeutics’ zuranolone, but Biogen CEO Chris Viehbacher wouldn’t spill it.The lack of prepared remarks or discussion of the would-be depression drug cooled Sage's shares, which dropped 8% over Tuesday after Biogen’s second